Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06467825 · ClinicalTrials.gov registry record · NA

Effect of Sex on Orthostatic Intolerance and Cardiovascular Response During Lunar Descent and Ascent

A NA study of Healthy, sponsored by National Aeronautics and Space Administration (NASA).

Recruiting
Registry status
NA
Development phase
38
Enrollment target
1
Study location

NCT06467825: Recruiting NA study of Healthy, sponsored by National Aeronautics and Space Administration (NASA).

NCT06467825 is a NA study of Healthy that is actively recruiting participants, run by National Aeronautics and Space Administration (NASA). The registered enrollment target is 38 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06467825, a NA study of Healthy, is actively recruiting participants, sponsored by National Aeronautics and Space Administration (NASA).

RECRUITING
Registry status
NA
Development phase
38 participants
Enrollment target
1
Study location

Study Summary

The purpose of Lunar OI (Orthostatic Intolerance) is to determine if there are differences between males and females in tolerance to and cardiovascular responses during different angles of head-up tilt simulating gravity levels less than or equal to Earth's gravity. Also, this study will determine if a gradient compression garment affects tolerance to tilting and the cardiovascular stress at different tilt angles. Males and females are being identified by biological sex. This will be a two-phased study design. In Phase I we will determine whether there are differences in the development of signs or symptoms of orthostatic intolerance between males and females when tilted head up on a table to different angles to simulate gravity levels that astronauts may experience when landing on or launching from the surface of the Moon. In Phase II, the tilt tests simulating the same gravity levels from Phase I will be repeated, but a custom-made lower-body compression garment will be worn to see if wearing the garment affects the development of orthostatic intolerance. For both study phases, before tilting, a drug will be administered to reduce the amount fluid in the blood (plasma) to levels similar to that experienced by astronauts during spaceflight.

Primary Outcome

Plasma volume and change in plasma volume is calculated using the Dill and Costill equation cited here: Dill DB, Costill DL. Calculation of percentage changes in volumes of blood, plasma, and red cells in dehydration.

Conditions Studied

Interventions

  • DRUG Potassium Supplement
  • DRUG Furosemide 20 MG
  • DEVICE Compression Garment

Study Locations (1)

Texas

  • NASA - Houston

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2022-08-09
Est. Completion 2025-09
Phase NA

What NCT06467825 shows while recruiting

NCT06467825 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Potassium Supplement is the first listed.

NCT06467825 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06467825 about?

NCT06467825 is a clinical study titled "Effect of Sex on Orthostatic Intolerance and Cardiovascular Response During Lunar Descent and Ascent". The purpose of Lunar OI (Orthostatic Intolerance) is to determine if there are differences between males and females in tolerance to and cardiovascular responses during different angles of head-up tilt simulating gravity levels less than or equal to Earth's gravity. Also, this study will determine i...

What is the current status of trial NCT06467825?

This trial is currently recruiting. It is a NA study. The enrollment target is 38 participants. The study started on 2022-08-09. Estimated completion is 2025-09.

What conditions does trial NCT06467825 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT06467825?

The interventions under investigation include: Potassium Supplement (DRUG), Furosemide 20 MG (DRUG), Compression Garment (DEVICE).

Who is sponsoring clinical trial NCT06467825?

This trial is sponsored by National Aeronautics and Space Administration (NASA), which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06467825 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06467825's enrollment target sits among peer trials

38 582nd of 1090 higher than 502 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01684904 · 38 participants · NA

    Proton Therapy for Esophageal Cancer

  • NCT03310879 · 38 participants · Phase 2

    Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

  • NCT03896269 · 38 participants · Phase 1

    CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • NCT04085315 · 38 participants · Phase 1

    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06467825, the US trial registry maintained by the National Library of Medicine. NCT06467825 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.